Cyclooxygenase and lipoxygenase inhibitors in cancer therapy

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 54, Issue 1, 1996, Pages 3-16

  Ara, G ^a   Teicher, B A ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

A 69412; ACETYLSALICYLIC ACID; CURCUMIN; ESCULIN; IBUPROFEN; INDOMETACIN; LIPOXYGENASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; NORDIHYDROGUAIARETIC ACID; PHENIDONE; PIROXICAM; PROSTAGLANDIN DERIVATIVE; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; SILEUTON; SULINDAC; UNCLASSIFIED DRUG;

ARACHIDONIC ACID METABOLISM; BREAST CANCER; CANCER; COLON CANCER; CONFERENCE PAPER; HEAD AND NECK CANCER; HUMAN; IMMUNE RESPONSE; LUNG CANCER; MACROPHAGE ACTIVATION; METASTASIS; NONHUMAN; PRIORITY JOURNAL;

EID: 0029931073     PISSN: 09523278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-3278(96)90075-7     Document Type: Conference Paper

References (188)

1. Honn K V, Busse W D, Sloane B F. Commentary - Prostacyclin and thromboxane: implications for their role in tumor cell metastasis. Biochem Pharmacol 1983; 32: 1-11.
2. Maca R D. Inhibition of the growth of Lewis lung carcinoma by indomethacin in conventional, nude, and beige mice. J Biol Resp Mod 1988; 7: 568-580.
3. Vlodavsky I, Korner G, Ishai-Michaeli R, Bashkin P, Bar-Shavit R, Fuks Z. Extracellular matrix-resident growth factors and enzymes: possible involvement in tumour metastasis and angiogenesis. Cancer Metastasis Rev 1990; 9: 203-226.
4. Marnett L J. Aspirin and the potential role of prostaglandins in colon cancer. Cancer Res 1992; 52: 5575-5589.
5. Oates J A, Fitzgerald G A, Branch R A, Jackson E K, Knapp H R, Roberts L J. Medical progress: clinical implications of prostaglandin and thromboxane A2 formation. N Engl J Med 1988; 319: 689-698.
6. Samuelsson B, Dahlén S-E, Lindgren J A, Rouzer C A, Serhan C N. Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science 1987; 237: 1171-1176.
7. Smith W L. The eicosanoids and their biochemical mechanisms of action. Biochem 1989; 259: 315-324.
8. Plescia O J. Does prostaglandin synthesis effect in vivo tumour growth by altering tumour/host balance? In: Powles T J, Bockman R S, Honn K V, Ramwell P eds. Prostaglandins and cancer: first international conference. New York: Alan R. Liss, 1982: 619-631.
9. Salmon S E. Interrelationship of endogenous macrophages, prostaglandin synthesis and tumor cell clonogenicity in human tumor biopsies. In: Powles T J, Bockman R S, Honn K V, Ramwell P eds. Prostaglandins and cancer: first international conference. New York: Alan R. Liss, 1982: 633-649.
10. Goodwin J S, Ceuppens J L. Prostaglandins, cellular immunity and cancer. In: Goodwin J S ed. Prostaglandins and immunity. Boston: Martinus Nijhoff, 1985: 1-34.
11. Plescia O J, Smith A H, Grinwich K. Subversion of immune system by tumor cells and role of prostaglandins. Proc Natl Acad Sci USA 1975; 72: 1848-1854.
12. Hwang D. Essential fatty acids and immune response. FASEB J 1989; 3: 2052-2061.
13. Young MRI, Young M E, Kim K. Regulation of tumor-induced myelopoiesis and the associated immune suppressor cells in mice bearing metastatic Lewis lung carcinoma by prostaglandin E2. Cancer Res 1988; 48: 6826-6831.
14. 2-producing nonmetastatic Lewis lung carcinoma variants. Cancer Res 1990; 50: 2973-2978.
15. Zwilling B S, Justement L B. Prostaglandin regulation of macrophage function. In: Heppner G H, Fulton A M eds. Macrophages and Cancer. Boca Raton, FL: CRC Press, 1988: 61-78.
16. Ruco L, Meltzer M S. Macrophage activation for tumor cytotoxicity: development of macrophage cytotoxic activity requires completion of a sequence of short-lived intermediary reactions. J Immunol 1978; 121: 2035-2042.
17. Taffet S M, Russell S W. Macrophage mediated tumor cell killing: regulation of expression of cytolytic activity by prostaglandin E. J Immunol 1981; 26: 424-427.
18. 2. J Immunol 1981; 127: 121-124.
19. 2. J Leukot Biol 1984; 35: 291-301.
20. Beckerman K P, Schreiber R D, Needleman P. Cytokine modulation of immune activation associated suppression of macrophage cyclooxygenase activity in vivo. Prostaglandins Leukot Essential Fatty Acids 1992; 47: 231-238.
21. Kunkel S L, Wiggins R C, Chensue S W, Larrick J. Regulation of macrophage tumor necrosis factor production by prostaglandin E2. Biochem Biophys Res Commun 1986; 137: 404-410.
22. Polverini P J. Macrophage-induced angiogenesis: a review. In: Song C, ed. Macrophage-derived cell regulatory factors. Cytokines Basel: Karger, 1989: 54-73.
23. Hokin L E. Receptors and phosphoinositide-generated second messengers. Annu Rev Biochem 1985; 54: 205-235.
24. Berridge M J. Calcium oscillations. J Biol Chem 1990; 265: 9583-9586.
25. Parker J, Daniel L W and Waite M: Evidence of protein kinase C involvement in phorbol diester-stimulated arachidonic acid release and prostaglandin synthesis. J Biol Chem 1987; 262: 5385-5393.
26. Needleman P, Turk J, Jakschik B A, Morrison A R and Lefkowith J B: Arachidonic acid metabolism. Ann Rev Biochem 1986; 55: 69-102.
27. Capdevila J H, Falck J R and Estabrook R W: Cytochrome P450 and the arachidonate cascade. FASEB J 1992; 6: 731-736.
28. Nugteren D H: Arachidonate lipoxygenase in blood platelets. Biochem Biophys Acta 1975; 380: 299-307.
29. Hamberg M, Svensson J, Wakabayashi T and Samuelsson B: Isolation and structure of two prostaglandin endoperoxides that cause platelet aggregation. Proc Nat Acad Sci USA 1974; 71:345-349.
30. Nugteren D H and Hazelhof B: Isolation and properties of intermediates in prostaglandins biosynthesis. Biochim Biophys Acta 1973; 326: 448-461.
31. Hamberg M and Samuelsson B: Prostaglandin endoperoxides: novel transformations of arachidonic acid in human platelets. Proc Nat Acad Sci USA 1974; 71: 3400-3404.
32. 4. In: Biological Response Mediators and Modulators. ed. Academic Press, Inc. 1983; 49-57.
33. Corey E J, Manfat A, Goto G and Brion F: Leukotriene B total synthesis and assignment of stereochemistry. J Am Chem Soc 1980; 102: 7984-7985.
34. Lewis R A, Goetzl E J, Drazen J M, Soter N A, Austein K F and Corey E J: Functional characterization of synthetic leukotriene B and its stereochemical isomers. J Exp Med 1981; 154: 1243-1248.
35. Lands WEM and Samuelsson B: Phospholipid precursors of prostaglandins. Biochim Biophys Acta 1968; 164: 426-429.
36. Vonkeman H and Van Dorp D A: The action of prostaglandin synthetase on 2-arachidonyl-lecithin. Biochim Biophys Acta 1968; 164: 430-432.
37. 1. Ann Surg 1990; 212: 45-50.
38. Lynch N R, Casatles M, Astonin M, Salomon J C. Mechanism of inhibition of tumor growth by aspirin and indomethacin. Br J Cancer 1978; 38: 503-509.
39. Lee P-P H, Ip M M. Regulation of proliferation of rat mammary tumor cells by inhibitors of cyclooxygenase and lipoxygenase. Prostaglandins Leukot Essential Fatty Acids 1992; 45: 21-31.
40. Bennett A, Houghton J, Leaper D J, Stamford IF. Cancer growth, response to treatment and survival time in mice: beneficial effect of the prostaglandin synthesis inhibitor fluribiprofen. Prostaglandins 1979; 17: 179-191.
41. Karmali R A, Welt S, Thaler H T, Lefevre F. Prostaglandins in breast cancer: relationship to disease stage and hormone status. Br J Cancer 1983; 48: 689-696.
42. Watson J, Chuah S Y. Prostaglandins, steroids and human mammary cancer. Eur J Cancer Clin Oncol 1985; 21: 1051-1055.
43. Bennett A, McDonald A M, Stamford IF. Prostaglandins and breast cancer. Lancet 1977; ii: 623-625.
44. 2α in benign and malignant breast tumors. Br J Cancer 1985; 51: 827-836.
45. Carter C A, Milholland RJ, Shea W, Ip M M. Effect of the prostaglandin synthetase inhibitor indomethacin on 7,12-dimethylbenz(a)anthracene-induced mammary tumorigenesis in rats fed different levels of fat. Cancer Res 1983; 43: 3559-3562.
46. McCormick D L, Madigan M J, Moon R C. Modulation of rat mammary carcinogenesis by indomethacin. Cancer Res 1985; 45: 1803-1808.
47. McCormick D L, Moon R C. Inhibition of mammary carcinogenesis by flurbiprofen, a non-steroidal anti-inflammatory agent. Br J Cancer 1983; 48: 859-861.
48. Hillyard L A, Abraham S. Effect of dietary polyunsaturated fatty acids on growth of mammary adenocarcinomas in mice and rats. Cancer Res 1979; 39: 4430-4437.
49. Fulton A M. In vivo effects of indomethacin on the growth of murine mammary tumors. Cancer Res 1984; 44: 2416-2420.
50. Hubbard W C, Alley M C, Gray G N, Green K C, McLemore T L, Boyd M R. Evidence for prostanoid biosynthesis as a biochemical feature of certain subclasses of non-small cell carcinomas of the lung as determined in established cell lines derived from human lung tumors. Cancer Res 1989; 49: 826-832.
51. Hubbard W C, Alley M C, McLemore T L, Boyd M R. Evidence for thromboxane biosynthesis in established cell lines derived from human lung adenocarcinomas. Cancer Res 1988; 48: 2674-2677.
52. Ellis L M, Copeland E M, Bland K I, Sitren H S. Differential role of prostaglandin E1 on tumor metastasis. J Surg Oncol 1990; 48: 333-336.
53. Hubbard W C, Alley M C, McLemore T L, Boyd M R. Fatty acid cyclooxygenase metabolism of arachidonic acid in human tumor cells. In: Eicosanoids and other bioactive lipids in cancer and radiation injury. Norwell M A, ed. Dordrecht: Kluwer, 1991:27-32.
54. Scher M G, Beller D I, Unanue E R. Demonstration of a soluble mediator that induces exudates rich in la-positive macrophages. J Exp Med 1980; 152: 1684-1690.
55. Fulton A M, Heppner G H. Relationships of prostaglandin E and natural killer sensitivity to metastatic potential in murine mammary adenocarcinomas. Cancer Res 1985; 45: 4779-4784.
56. Kollmorgen G M, King M M, Kosanke S D, Do C. Influence of dietary fat and indomethacin on the growth of transplantable mammary tumors in rats. Cancer Res 1983; 43: 4714-4719.
57. Nagasawa H, Naito T. Inhibition by indomethacin of spontaneous mammary tumorigenesis in SHN mice. Breast Cancer Res Treatment 1986; 8: 249-255.
58. Hubbard N E, Chapkin R S, Erickson K L Inhibition of growth and linoleate-enhanced metastasis of a transplantable mouse mammary tumor of indomethacin. Cancer Lett 1988; 43: 111-120.
59. Hendrick A M, Mitchell M D, Harris A L, Thearle P B. Plasma prostaglandins in lung cancer. Eur J Cancer Clin Oncol 1988; 24: 1069-1071.
60. Heinonen P K, Metsa-Ketela T. Prostanoids and cyclic nucleotides in malignant and benign ovarian tumors. Med Oncol Tumor Pharmacother 1988; 5: 11-15.
61. Vanderveen E E, Grekin R C, Swanson N A. Arachidonic acid metabolites in cutaneous carcinoma. Arch Dermatol 1986; 122: 407-412.
62. Bennet A, Carter L, Stamford I F. Prostaglandin-like material extracted from squamous carcinomas of the head and neck. Br J Cancer 1980; 41: 204-208.
63. Green K. Determination of prostaglandin in body fluids and tissues. Acta Obstet Gynaecol Scand 1979; 87 (Suppl): 15-20.
64. Vane J R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature New Biol 1971; 231: 232-235.
65. Vane J, Botting R. Inflammation and the mechanism of action of anti-inflammatory drugs. FASEB J 1988; 2: 89-96.
66. Robinson H J, Vane J R. Prostaglandin synthetase inhibitors - their effects on physiological functions and pathological states. New York: Raven Press, 1974.
67. Flower R J. Drugs which inhibit prostaglandin biosynthesis. Pharmacol Rev 1974; 26: 33-67.
68. DeWitt D L, El-Harith E A, Kraemer S A et al. The aspirin and heme-binding sites of ovine and murine prostaglandin endoperoxide synthases. J Biol Chem 1990; 265: 5192-5198.
69. Lands W E M, Hanel A M. Inhibitors and activators of prostaglandin biosynthesis. In: Pace-Asciak C, Granstrom E, eds. Prostaglandins and Related Substances. Amsterdam: Elsevier/North-Holland Biomedical Press, 1983: 203-223.
70. Roth G J, Majerus P W. The mechanism of the effect of aspirin on human platelets I: acetylation of a particulate fraction protein. J Clin Invest 1975; 56: 624-632.
71. Rome L H, Lands W E M, Roth G J, Majerus P W. Aspirin as a quantitative acetylating reagent for the fatty acid oxygenase that forms prostaglandins. Prostaglandins 1976; 11: 23-30.
72. Garland L G, Salmon J A. Hydroxamic acids and hydroxyureas as inhibitors of arachidonate 5-lipoxygenase. Drugs Future 1991; 16: 547-558.
73. Bell R L, Bouska R, Young P R et al. The properties of A-69412: a small hydrophilic 5-lipoxygenase inhibitor. Agents Actions 1993; 38: 178-187.
74. Bell R L, Lanni C, Malo P E et al. Preclinical and clinical activity of zileuton and A-78773. Ann NY Acad Sci 1993; 696: 205-215.
75. Bell R L, Young P R, Albert D et al. The discovery and development of zileuton: an orally active-lipoxygenase inhibitor. Int J Immunopharmacol 1992; 14: 505-510.
76. Rao C V, Rivenson A, Simi B et al. Chemoprevention of colon carcinogenesis by sulindac, a non-steroidal anti-inflammatory agent. Cancer Res 1995; 55: 1464-1472.
77. Rome L H, Lands W E M. Structural requirements for time-dependent inhibition of prostaglandin biosynthesis by anti-inflammatory drugs. Proc Natl Acad Sci USA 1975; 72: 4863-4865.
78. 2 in plasma samples from patients with benign and malignant tumours of the breast. Prostaglandins 1985; 29: 513-528.
79. McCormick D L, Spicer A M. Nordihydroguaiaretic acid suppression of rat mammary carcinogenesis induced by W-methyl-N-nitrosourea. Cancer Lett 1987; 37: 139-146.
80. Rose D P, Connolly J M, Liu X-H. Effects of linoleic acid on the growth and metastasis of two human breast cancer cell lines in nude mice and the invasive capacity of these cell lines in vitro. Cancer Res 1994; 54: 6557-6562.
81. Rose D P, Connolly J M. Effects of fatty acids and inhibitors of eicosanoid synthesis on the growth of a human breast cancer cell line in culture. Cancer Res 1990; 50: 7139-7144.
82. Rose D P, Connolly J M, Meschter C L. Effect of dietary fat on human breast cancer growth and metastasis in nude mice. J Natl Cancer Inst 1991; 83: 1491-1495.
83. Corey E J, Shih C, Cashman J R. Docosahexaenoic acid is a strong inhibitor of prostaglandin but not leukotriene synthesis. Proc Natl Acad Sci USA 1983; 80: 3581-3584.
84. Feldman J M, Hilf R. Failure of indomethacin to inhibit growth of the R3230AC mammary tumor in rats. J Natl Cancer Inst 1985; 75: 751-756.
85. Cohen L A, Karmali R A. Endogenous prostaglandin production by established cultures of neoplastic rat mammary epithelial cells. In vitro 1984; 20: 119-126.
86. Higgs G A, Moncada S, Vane J R. The mode of action of anti-inflammatory drugs which prevent the peroxidation of arachidonic acid. Anti-Rheumatic Drugs 1983: 11-36.
87. Radmark O, Malmsten C, Sameulsson B. The inhibitory effects of BW-755C on arachidonic acid metabolism in human polymorphonuclear leukocytes. FEBS Lett 1980; 110: 213-215.
88. Ahnfelt-Ronne I, Arrigoni-Martelli E. Multiple effects of a new anti-inflammatory agent, timegadine, on arachidonic acid release and metabolism in neutrophils and platelets. Biochem Pharmacol 1982; 31: 2619-2624.
89. Bandyopadhyay G K, Imagawa W, Wallace D, Nandi S. Linoleate metabolites enhance the in vitro proliferative response of mouse mammary epithelial cells to epidermal growth factor. J Biol Chem 1987; 262: 2750-2756.
90. 2. J Biol Chem 1988; 263: 7567-7573.
91. Boring C C, Squires T S, Tong T, Montgomery S. Cancer statistics. Cancer J Clin 1994; 44: 7-26.
92. Reddy B S, Rao C V, Rivenson A, Kelloff G J. Inhibitory effect of aspirin on azoxymethane-induced colon carcinogenesis in F344 rats. Carcinogenesis 1993; 14: 1493-1497
93. Honn K V, Gropssi I M, Steinert B W et al. Lipoxygenase regulation of membrane expression of tumor cell glycoproteins and subsequent metastasis. Adv Prostaglandin Thromboxane Leukot Res 1989; 19: 439-443.
94. Timer J, Chen Y Q, Liu B, Bazar R, Taylor J D, Honn K V. The lipoxygenase metabolite 12(S)-HETE promotes αIIb β3 integrin-mediated tumor-cell spreading on fibronectin. Int J Cancer 1992; 52: 594-603.
95. Honn K V, Tang D G. Adhesion molecules and cancer cell interaction with endothelium and subendothelial matrix. Cancer Metastasis Rev 1992; 11: 353-375.
96. Fstenbüeger G, Schurich B, Kaina B, Petrusevska R T, Fuesning N E, Marks F. Tumor induction in initiated mouse skin by phorbol esters and methyl methanesulfonate: correlation between chromosomal damage and conversion ("stage I of tumor promotion") in vivo. Carcinogenesis 1989; 10: 749-752.
97. Fischer S M, Baldwin J K, Jasheway R W, Patrick K E, Cameron G S. Phorbol ester induction of 8-lipoxygenase in inbred SENCAR (SSIN) but not C57BL/6J mice correlated with hyperplasia, edema, and oxidant generation by ornithine decarboxylase induction. Cancer Res 1988; 48: 658-664.
98. Bond L, Hagege J, Sraer J, Rondeau E, Perez J, Ardaillau R. Reactive oxygen production by cultured rat glomerular mesangial cells during phagocytosis is associated with stimulation of lipoxygenase activity. J Exp Med 1993; 158: 1836-1852.
99. Waddell W R, Ganser G F, Cerise E J, Loughry R W. Sulindac for polyposis of the colon. Am J Surg 1990; 41: 891-894.
100. 2 and liver and lung metastases in colorectal cancer. Dis Colon Rectum 1990; 33: 840-845.
101. Smith W L. Prostanoid biosynthesis and mechanisms of action. Am J Physiol 1992; 263: F181-F191.
102. Rao C V, Rivenson A, Katiwalla M, Kelloff G J, Reddy B S. Chemopreventive effect of oltipraz during different stages of experimental colon carcinogenesis induced by azoxymethane in male F344 rats. Cancer Res 1993; 53: 2502-2506.
103. Hyman A L, Spannhake E W, Kadowitz P J. State of the art: prostaglandins and the lung. Am Rev Respir Dis 1978; 117: 111-136.
104. Newman J H, Sheller J R. Review: arachidonic acid metabolites in the healthy and diseased lung. Am J Med Sci 1984; 288: 75-80.
105. Mathe A A, Hedqvist P, Strandberg IF, Leslie C A. Aspects of prostaglandin function in the lung (two parts). N Engl J Med 1977; 296: 850-855, 910-914.
106. Seyberth H W, Segre G V, Morgan J L, Sweetman B J, Potts J J T, Oates J A. Prostaglandins as mediators of hypercalcemia associated with certain types of cancer. N Engl J Med 1975; 293: 1278-1283.
107. Bennett A, Carroll M A, Stamford IF, Whimster W F, Williams F. Prostaglandins and human lung carcinomas. Br J Cancer 1982; 46: 888-893.
108. Lau S S, McMahon J B, McMenamin M G, Schuller H M, Boyd M R. Differential metabolism of arachidonic acid in human lung carcinoma cell lines. Cancer Res 1987; 47: 3757-3762.
109. Hubbard W C, Alley M C, McLemore T L, Boyd M R. Evidence for thromboxane biosynthesis in a human lung adenocarcinoma cell line, A549. Fed Proc 1987; 46: 692.
110. Honn K V, Bockman R S, Marnett L J. Prostaglandins and cancer: a review of tumor initiation through tumor metastasis. Prostaglandins 1981; 21: 833-850.
111. Fischer S M, Slaga T J. Modulation of prostaglandin synthesis and tumor promotion. In: Powles T J, Bockmann R S, Honn K V, Ramwell P W eds. Prostaglandins and related lipids. New York: Alan R. Liss, 1984: 255-261.
112. Fischer S A. Arachidonate cascade and skin tumor promotion. In: Thaler-Dao H, Crastes de Paulet A, Paoletti R eds. Icosanoids and cancer. New York: Raven Press 1984: 79-90.
113. Kato R, Nakadate T, Yamamoto S. Involvement of lipoxygenase products of arachidonic acid in tumor promoting activity of TPS. In: Thaler-Dao H, Crastes de Paulet A, Paoletti R eds. Icosanoids and cancer. New York: Raven Press, 1984: 101-114.
114. Levine L, Goldstein S M, Snoek G T, Rigas A. Arachidonic acid metabolism by cells in culture: effect of tumor promoters. In: Thaler-Dao H, Crastes de Paulet A, Paoletti R eds. Icosanoids and cancer. New York: Raven Press, 1984: 115-121.
115. Sydney E, Salmon M D. Interrelationship of endogenous macrophages, prostaglandin synthesis and tumor cell clonogenicity in human tumor biopsies. In: Powles T, Bockman TJ, Honn K V, Ramwell P eds. Prostaglandin and cancer. First international conference. New York: Alan R. Liss, 1984: 633-651.
116. 2-responsive metastatic Lewis lung carcinoma cells. Cancer Res 1987; 47: 3679-3683.
117. 2 on macrophage mediated cytotoxicity. In: Forster W ed. International workshop: Heterogeneity of mononuclear phagocytes. New York: Academic Press, 1981: 428-461.
118. 2-induced inhibition of interleukin-2 production. J Immunol 1983; 130: 1770-1778.
119. 2. Immunol Commun 1982; 11: 345-352.
120. Verma A, Ashendel C L, Boutwell R K. Inhibition by prostaglandin synthesis inhibitors of the induction of epidermal ornithine decarboxylase activity, the accumulation of prostaglandins and tumor promotion caused by 12-O-tetradecanoyl-phorbol-13-acetate. Cancer Res 1980; 40: 308-312.
121. Levine L. Arachidonic acid transformation and tumor production. Adv Cancer Res 1981; 35: 49-52.
122. Rolland P H, Martin P M, Jaquemier J, Rolland A M, Toga M. Prostaglandins in human breast cancer: evidence suggesting that an elevated prostaglandin production is a marker of high metastatic potential for neoplastic cells. J Natl Cancer Inst 1980; 64: 1061-1068.
123. McLemore T L, Hubbard W C, Litterst C L et al. Profiles of prostaglandin biosynthesis in normal lung and tumor tissue from lung cancer patients. Cancer Res 1988; 48: 3140-3147.
124. Selawry O S, Hansen H H. Lung cancer. In: Holland J F, Frei E eds. Cancer medicine. Philadelphia: Lea & Febiger, 1982: 1735-1739.
125. Chiabrando C, Broggini M, Castagnoli M N et al. Prostaglandin and thromboxane synthesis by Lewis lung carcinoma during growth. Cancer Res 1985; 45: 3605-3608.
126. Hubbard W C, Alley M C, McLemore T L, Boyd M R. Profiles of prostaglandin biosynthesis in sixteen established cell lines derived from human lung, colon, prostate, and ovarian tumors. Cancer Res 1988; 48: 4770-4775.
127. Teicher B A, Korbut T T, Menon K, Holden S A, Ara G. Cyclooxygenase and lipoxygenase inhibitors as modulators of cancer therapies. Cancer Chemother Pharmacol 1994; 33: 515-522.
128. Berlinger N T. Deficient immunity in head and neck cancer due to excessive monocyte production of prostaglandins. Laryngoscope 1984; 94: 1407-1410.
129. 2 of the upper aerodigestive tract. Ann Otol Rhinol Laryngol 1987; 96: 213-216.
130. Pinto S, Gallo O, Dilaghi M et al. Prostaglandins in squamous cell carcinoma of the larynx: tumor and peritumor synthesis. Prostaglandins Leukot Essential Fatty Acids 1990; 39: 53-57
131. Klapan I, Katic V, Culo F, Cuk V. Prognostic significance of plasma prostaglandin E concentration in patients with head and neck cancer. Cancer Res Clin Oncol 1992; 118: 308-313.
132. 2α. Proc Natl Acad Sci USA 1975; 72: 2724-2728.
133. Honn K V, Meyer J. Thromboxanes and prostacyclin: positive and negative modulators of tumor growth. Biochem Biophys Res Commun 1981; 102: 1122-1129.
134. Honn K V, Meyer J, Neagos G, Henderson T, Westley C, Ratanatharathorn V. Control of tumor growth and metastasis with prostacyclin and thromboxane synthetase inhibitors: evidence for a new antitumor and antimetastatic agent (Bay g 6575). In: Jamieson G A, ed. Interaction of Platelets and Tumor Cells. New York: Alan R. Liss, 1982: 295-331.
135. Partin A W, Isaacs J T, Treiger B, Coffey D S. Early cell motility changes associated with an increase in metastatic ability in rat prostatic cancer cells transfected with the v-Harvey-ras oncogene. Cancer Res 1988; 48: 6050-6053.
136. 2 secretion by cloned variants of Lewis lung carcinoma. Cancer Res 1985; 45: 3918-3923.
137. Verma A K, Rice H M, Boutwell R K. Prostaglandins and skin tumor promotion: inhibition of tumor promoter-induced ornithine decarboxylase activity in epidermis by inhibitors of prostaglandin synthesis. Biochem Biophys Res Commun 1977; 79: 1160-1166.
138. 2 in mouse epidermis in vivo. Biochem Biophys Res Commun 1978; 84: 1103-1111.
139. Mohler J L, Partin A W, Isaacs J T, Coffey D S. Metastatic potential prediction by a visual grading system of cell motility: prospective validation in the Dunning R-3327 prostatic adenocarcinoma model. Cancer Res 1988; 48: 4312-4317.
140. Maslow D E, Goldrosen M H. Relationship in in vitro cell motility and colonization potential in a mouse colon adenocarcinoma (MCA-38) cell line. Invasion Metastasis 1988; 8: 133-142.
141. Nabi I R, Raz A. Loss of metastatic responsiveness to cell shape modulation in a newly characterized B16 melanoma adhesive cell variant. Cancer Res 1988; 48: 1258-1264.
142. Varani J, Fligiel S E G. Perone P. Directional motility in strongly malignant murine tumor cells. Int J Cancer 1985; 35: 559-564.
143. Fulton A M. The role of eicosanoids in tumor metastasis. Prostaglandins Leukot Essential Fatty Acids 1988; 34: 229-237.
144. Fulton A M. Effects of indomethacin on the growth of culture mammary tumors. Int J Cancer 1984; 33: 375-379.
145. 2 formation by malignant melanoma cells correlates inversely with cellular metastatic potential. Proc Natl Acad Sci USA 1979; 76: 1765-1769.
146. 2 and related compounds: an update. Prostaglandins Leukot Essential Fatty Acids 1992; 47: 1-12.
147. 2 controls pulmonary metastasis of malignant melanoma cells. Nature 1979; 282: 76-78.
148. Liebeskind L S, Mitchell D, Foster B S. A stereoselective, palladium-catalyzed route to 4-oxygenated 5-alkylidene cyclopentenones and 3-oxygenated 2-alkylidene indanones. J Am Chem Soc 1987; 109: 7908-7910.
149. Liebeskind L S, Chidambaram R, Mitchell D, Foster B S. Metal mediated routes to 5-membered rings. Pure Appl Chem 1988; 60: 27-34.
150. Fukushima M. Prostaglandin J2-anti-tumor and anti-viral activities and the mechanisms involved. Eicosanoids 1990; 3: 189-199.
151. Fulton A M. Interactions of natural effector cells and prostaglandins in the control of metastasis. J Natl Cancer Inst 1987; 78: 735-741.
152. Fukushima M, Kato T, Ueda R, Ota K, Narumiya S, Hayaishi O. Prostaglandin D2, a potential antineoplastic agent. Biochem Biophys Res Commun 1982; 105: 956-964.
153. Bregman M D, Meyskens F L J. In vitro modulation of human and murine melanoma growth by prostanoid analogues. Prostaglandins 1983; 26: 449-456.
154. Kikuchi Y, Miyauchi M, Oomori K, Kita T, Kizawa I, Kato K. Inhibition of human ovarian cancer cell growth in vitro and in nude mice by prostaglandin D2. Cancer Res 1986; 46: 3364-3366.
155. Kikuchi Y, Kita T, Miyauchi M et al. Adjuvant effects of antineoplastic prostaglandins to cisplatin in nude mice bearing human ovarian cancer cells. J Cancer Res Clin Oncol 1992; 118: 453-457
156. 2 in the glioma cell line C6. Anticancer Res 1991; 11: 289-296.
157. Castelli M G, Butti G, Chiabrando C et al. Arachidonic acid metabolic profiles in human meningiomas and gliomas. J Neurooncol 1987; 5: 369-375.
158. Baich C M, Doghert P A, Cloud G A, Tilden A B. Prostaglandin E2-mediated suppression of cellular immunity in colon cancer patients. Surgery 1984; 95: 71-77.
159. Tilden A B, Balch C M. Indomethacin enhancement of immunocompetence in melanoma patients. Surgery 1981; 90: 77-84.
160. Grinwich K D, Plescia O J. Tumor-mediated immunosuppression: prevention by inhibitors of prostaglandin synthesis. Prostaglandins 1977; 14: 1175-1183.
161. King D P, Jones P P. Induction of Ia and H-2 antigens on a macrophage cells line by immune Interferon. J Immunol 1983; 131:315-318.
162. Nathan C F, Murray H W, Wiebe M E, Rubin B Y. Identification of interferon-γ as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity. J Exp Med 1983; 158: 670-676.
163. Buchmeier N A, Schreiber R D. Requirement of endogenous interferon-γ production for resolution of Listeria monocytogenes infection. Proc Natl Acad Sci USA 1985; 82: 7404.
164. Schreiber R D, Hicks LJ, Celada A, Buchmeier N A, Gray P W. Monoclonal antibodies to murine γ-interferon which differentially modulate macrophage activation and antiviral activity. J Immunol 1985; 134: 1609-1619.
165. Guyre P M, Morganelli P M, Miller R. Recombinant immune interferon increases immunoglobulin G Fc receptors on cultured human mononuclear phagocytes. J Clin Invest 1983; 72: 392-397.
166. 2 in syrian hamster embryo cells. Cancer Res 1992; 52: 6912-6916.
167. Stearns M E, Wang M. Type IV collagenase (M, 72 000) expression in human prostate: benign and malignant tissue. Cancer Res 1993; 53: 878-883.
168. Tamargo RJ, Bok R A, Brem H. Angiogenesis inhibition by minocycline. Cancer Res 1991; 51: 672-675.
169. 2 in human breast cancer cells. Biochem J 1984; 224: 361-370.
170. Goldenring J R, Vallano M L, DeLorenzo RJ. Phosphorylation of microtubule-associated protein 2 at distinct sites by calmodulin-dependent and cyclic-AMP-dependent kinases. J Neurochem 1985; 45: 900-905.
171. Terranova V P, Hujanen E S, Martin G R. Basement membrane and the invasive activity of metastatic tumor cells. J Natl Cancer Inst 1986; 77: 311-316.
172. Narumiya S, Fukushima M. Site and mechanism of growth inhibition by prostaglandins: active transport and intracellular accumulation of cyclopentenone prostaglandins, a reaction leading to growth inhibition. J Pharmacol Exp Ther 1986; 239: 500-505.
173. Narumiya S, Ohno K, Fujiwara M, Fukushima M. Site and mechanism of growth inhibition by prostaglandins: temperature-dependent transfer of cyclopentenone prostaglandin to nuclei. J Pharmacol Exp Ther 1986; 239: 506-511.
174. 2 in nuclei. J Pharmacol Exp Ther 1987; 242: 306-311.
175. 2 in a fibroblastic cell line. Eicosanoids 1990; 3: 213-218.
176. 2+-stimulated ATPase of walker-256 tumour microsomal membranes. Anticancer Res 1989; 9: 753-760.
177. 2 activity: implications for inflammatory diseases. DNA Cell Biology 1992; 11: 233-243.
178. 2 and its regulatory factors. New York: Plenum, 1990.
179. 2 shows malignant potential of human breast cancer cells. Cancer 1993; 71: 3058-3064.
180. 2 dependent mechanisms. Prostaglandin Thromboxane Leukot Res 1990: 217-223.
181. 2 and the effects of arachidonic acid. J Biol Chem 1988; 263: 7506-7513.
182. Dennis E A. Cell activation and signal initiation: receptor and phospholipase control of inositol phosphate, PAF and eicosanoid production. In: Dennis E A, Hunter A, Berridge M eds. UCLA Symposium on molecular and cellular biology - New series. New York: Alan R. Liss 1989: 17-23.
183. 1 cell. Biol Chem 1989; 264: 8520-8528.
184. Goldman R, Ferber F, Zort U. Reactive oxygen species are involved in the activation of cellular phospholipase A2. FEBS Lett 1992; 309: 190-192.
185. Teicher B A, Holden S A, Chen Y-N, Ara G, Korbut T T, Northey D. CAI: effects on cytotoxic therapies in vitro and in vivo. Cancer Chemother Pharmacol 1994; 34: 515-522.
186. Kohn E C, Sandeen M A, Liotta L A. In vivo efficacy of a novel inhibitor of selected signal transduction pathways including calcium, arachidonate, and inositol phosphates. Cancer Res 1992; 52: 3208-3212.
187. Ludden L K, Strong J M, Kohn E C, Collins J M. Similarity of metabolism for CAI (NSC 609974) in human liver tissue in vitro and in humans in vivo. Clin Cancer Res 1995; 1: 399-405.
188. Felder C C, Ma A L, Liotta L A, Kohn E C. The antiproliferative and antimetastatic compound L651582 inhibits muscarinic acetylcholine receptor-stimulated calcium influx and arachidonic acid release. J Pharmacol Exp Ther 1991; 257: 967-971.